Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects. Eligibility: Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments Donors: Healthy people ages 18 and older whose relative has lymphoma Design: Participants will be screened with: Physical exam Blood and urine tests Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow. Donors will also be screened with: X-rays Recipients will also be screened with: Lying in scanners that take pictures of the body Tumor sample Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm. Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter. Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months. Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku od 12 lat z chłoniakiem obwodowym typu T, który nie reaguje na standardowe leczenie.
- •Potencjalny dawca komórek macierzystych: zdrowa osoba w wieku od 18 lat, spokrewniona z pacjentem.
- •Pacjent musi mieć odpowiednio działające narządy (serce, płuca, wątroba), co zostanie sprawdzone badaniami.
✗ Disqualifies
- •Chłoniak ALK-dodatni, który nie jest nawrotowy ani oporny na leczenie.
- •Pacjenci z istniejącymi poważnymi chorobami narządów uniemożliwiającymi przeszczep.
- •Pacjenci, którzy nie kwalifikują się ze względu na stan zdrowia lub inne czynniki oceniane przez lekarzy.
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
National Institutes of Health Clinical Center
Bethesda, United States
National Marrow Donor Program
Minneapolis, United States
Trial contact
Jessenia C Campos, R.N.
Dimana Dimitrova, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.